Clinical outcome of tailored adjuvant postoperative chemoradiotherapy in IB FIGO stage cervical cancer

Anticancer Res. 2009 Oct;29(10):4205-10.

Abstract

Aim: The aim of the present report is to review a mono-institutional experience of postoperative radiotherapy in selected patients with cervical cancer.

Patients and methods: Between 1999 and 2008, fifty-one patients with high-risk stage IB cervical cancer underwent tailored adjuvant postoperative radiotherapy; concurrent chemoradiotherapy was administered to patients presenting a high risk of recurrence. The median follow-up was 58 months.

Results: All patients were in complete remission at first follow-up assessment. Ten patients were subject to recurrences between 7 and 54 months after treatment. The 2-year and 5-year disease-free survival rates were 88.1% and 74.9%, respectively; 2-year and 5-year overall survival rates of the whole group were 91.8% and 82.0%, respectively. Only one case of grade 4 and four cases of grade 3 side effects were reported.

Conclusion: Tailored adjuvant postoperative chemoradiotherapy is able to obtain a satisfactory clinical outcome in patients with high-risk early-stage IB cervical cancer.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Brachytherapy
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Staging
  • Postoperative Care
  • Radiotherapy, Adjuvant
  • Retrospective Studies
  • Treatment Outcome
  • Uterine Cervical Neoplasms / drug therapy*
  • Uterine Cervical Neoplasms / pathology
  • Uterine Cervical Neoplasms / radiotherapy*
  • Uterine Cervical Neoplasms / surgery